The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

https://neurodegenerationresearch.eu/survey/the-alpha-tocopherol-beta-carotene-cancer-prevention-study/

Title of the cohort

The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

Acronym for cohort

ATBC Study

Name of Principal Investigator

Title	Research professor, MD, Ph.D
First name	Jarmo
Last name	Virtamo

Address of institution where award is held

Institution	The National Institute for Health and Welfare
Street Address	Mannerheimintie 166
City	Helsinki
Postcode	00330

Country

- Finland

Website

http://atbcstudy.cancer.gov

Contact email

jarmo.virtamo@thl.fi

Funding source

1. The cohort includes, or expects to include, incidence of the following conditions

- Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

- Already possible

2a. Stated aim of the cohort

ATBC Study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with alpha-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers among male smokers.

2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date

304

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)

http://atbcstudy.cancer.gov/publications/search/index.pl

4a. Study criteria: age range of participants at recruitment

Age in years from: 50
To ('until death' if applicable): 69

4b. Study criteria: inclusion criteria

Men of 50-69 years old smoking 5 or more cigarettes a day

4c. Study criteria: exclusion criteria

Men who had prior cancer or serious illness or who reported current use of vitamins E (>20 mg/day), A (>20,000 IU/day), or beta-carotene (>6 mg/day) were ineligible.

5. Size of the cohort (i.e. number of participants enrolled)

- More than 15,000

6a. Measures used to characterise participants

?

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

- No

7. Study design

- Longitudinal

8. Cases matched by

- Other health assessment (specify) / N/A
- no neurodegenerative case-control definition

9a. Does the study include a specialised subset of control participants

- No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-1985

10a. ii) Data collection end date

30-04-1993

10a iii) Data collection for this study is

- Data analysis ongoing
- Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date

- No

11. Data collected

- Through links to other records or registers (such as dental records, police records etc). Please specify
- Finnish cancer registry, morbidity registry

12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- National access
- International access
- Resource has own ethics approval so usually no need for separate external ethics approval

15. Data sharing policy specified as a condition of use

- Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

- Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

- No